Receptos prices upsized IPO at $14, the low end of the range

By
A A A

Receptos, a biotech developing treatments for relapsing multiple sclerosis and IBD, raised $73 million by offering 5.2 million shares (up from 4.7 million) at $14, the low end of the range of $14 to $16. Receptos plans to list on the NASDAQ under the symbol RCPT. Receptos initially filed confidentially on 2/13/2013. Credit Suisse, Leerink Swann and BMO Capital Markets acted as lead managers on the deal.




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: RCPT

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

100%

Most Active by Volume

7,625,175
  • $18.01 ▲ 0.17%
5,366,336
  • $68.26 ▲ 2.79%
4,842,470
  • $93.91 ▲ 2.87%
4,605,144
  • $112.6537 ▲ 0.57%
4,599,098
  • $8.36 ▲ 5.96%
4,595,946
  • $7.63 ▲ 0.39%
4,482,967
  • $12.73 ▼ 2.53%
4,322,225
  • $7.3899 ▲ 1.79%
As of 12/26/2014, 10:32 AM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com